PTC-518 is a small molecule commercialized by PTC Therapeutics, with a leading Phase II program in Huntington Disease. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of PTC-518’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for PTC-518 is expected to reach an annual total of $28 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
PTC-518 Overview
PTC-518 is under development for the treatment of Huntington disease. It is administered by oral route. The drug candidate acts by targeting huntingtin gene. It is developed based on alternative splicing technology platform.
See Also:
PTC Therapeutics Overview
PTC Therapeutics discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren) and Emflaza (deflazacort) for the treatment of Duchenne muscular dystrophy. The company’s pipeline candidates target the treatment of Huntington’s disease; children with inherited mitochondrial disease; leiomyosarcoma; acute myelogenous leukemia; and aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. It operates through its subsidiaries in the US and Europe. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.
The company reported revenues of (US Dollars) US$698.8 million for the fiscal year ended December 2022 (FY2022), an increase of 29.7% over FY2021. The operating loss of the company was US$447.4 million in FY2022, compared to an operating loss of US$374.4 million in FY2021. The net loss of the company was US$559 million in FY2022, compared to a net loss of US$523.9 million in FY2021.
The company reported revenues of US$196.6 million for the third quarter ended September 2023, a decrease of 8.1% over the previous quarter.
For a complete picture of PTC-518’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.